Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Dec 12, 2022
- Pharmaceuticals
- R&D
Roche Presents Data at American Society of Hematology (ASH) Annual Meeting
TOKYO, December 12, 2022 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on data presentation regarding therapeutic antibodies created by Chugai, Hemlibra® and crovalimab, at the American Society of Hematology (ASH) Annual Meeting.
Please refer to the link below for details:
- Interim data from phase III study presented at ASH 2022 show Hemlibra achieved meaningful bleed control in infants from birth
https://www.roche.com/media/releases/med-cor-2022-12-11b - Roche’s subcutaneous crovalimab given every four weeks achieves disease control in people with PNH, a life-threatening blood condition
https://www.roche.com/media/releases/med-cor-2022-12-11
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp